AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyObservationalPeer-reviewed
Autologous haematopoietic stem cell transplantation affects paramagnetic rim lesions in multiple sclerosis
In a study of 30 people with multiple sclerosis undergoing AHSCT, reductions in paramagnetic rim lesion (PRL) count were observed. In a group followed pre and post-AHSCT, 40% of PRL-positive individuals showed decreased PRL counts, while 19% had resolved lesions. In the post-AHSCT group, 57% of PRL-positive cases showed decreases, with 50% resolution and no new lesions appearing.
- Tags
- #Other
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
Why it matters
These findings suggest that AHSCT may facilitate the reduction of harmful PRLs in the brain, potentially indicating an impact on inflammation that could influence disease progression.
What this does not prove
The study's limited size, absence of a control group, and being monocentric restrict the broader applicability of its findings. Additionally, causation cannot be established from this observational data.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 30 · total participants in the study
- Randomised
- No
- Controlled
- No
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-08
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Other
Original sources
- Primary evidenceAutologous haematopoietic stem cell transplantation affects paramagnetic rim lesions in multiple sclerosis. ↗DOI: 10.1177/13524585261489061
Supporting passages (15)
study phaseMETHODS: Monocentric study including 30 AHSCT-treated people with multiple sclerosis who performed at least two brain magnetic resonance imaging scans with susceptibility-weighted imaging either (i) before and after AHSCT (pre/post-AHSCT group; n = 12) or (ii) after AHSCT only (post-AHSCT group; n = 18).
study designMETHODS: Monocentric study including 30 AHSCT-treated people with multiple sclerosis who performed at least two brain magnetic resonance imaging scans with susceptibility-weighted imaging either (i) before and after AHSCT (pre/post-AHSCT group; n = 12) or (ii) after AHSCT only (post-AHSCT group; n = 18).
subjectsMETHODS: Monocentric study including 30 AHSCT-treated people with multiple sclerosis who performed at least two brain magnetic resonance imaging scans with susceptibility-weighted imaging either (i) before and after AHSCT (pre/post-AHSCT group; n = 12) or (ii) after AHSCT only (post-AHSCT group; n = 18).
sample sizeMETHODS: Monocentric study including 30 AHSCT-treated people with multiple sclerosis who performed at least two brain magnetic resonance imaging scans with susceptibility-weighted imaging either (i) before and after AHSCT (pre/post-AHSCT group; n = 12) or (ii) after AHSCT only (post-AHSCT group; n = 18).
sample size basisMETHODS: Monocentric study including 30 AHSCT-treated people with multiple sclerosis who performed at least two brain magnetic resonance imaging scans with susceptibility-weighted imaging either (i) before and after AHSCT (pre/post-AHSCT group; n = 12) or (ii) after AHSCT only (post-AHSCT group; n = 18).
randomizedMETHODS: Monocentric study including 30 AHSCT-treated people with multiple sclerosis who performed at least two brain magnetic resonance imaging scans with susceptibility-weighted imaging either (i) before and after AHSCT (pre/post-AHSCT group; n = 12) or (ii) after AHSCT only (post-AHSCT group; n = 18).
controlledMETHODS: Monocentric study including 30 AHSCT-treated people with multiple sclerosis who performed at least two brain magnetic resonance imaging scans with susceptibility-weighted imaging either (i) before and after AHSCT (pre/post-AHSCT group; n = 12) or (ii) after AHSCT only (post-AHSCT group; n = 18).
peer reviewedMETHODS: Monocentric study including 30 AHSCT-treated people with multiple sclerosis who performed at least two brain magnetic resonance imaging scans with susceptibility-weighted imaging either (i) before and after AHSCT (pre/post-AHSCT group; n = 12) or (ii) after AHSCT only (post-AHSCT group; n = 18).
research categoriesCONCLUSIONS: Given the reported long persistence of PRLs, these data indicate that AHSCT may accelerate their disappearance, suggesting an effect within the central nervous system on microglia/macrophages.
publication dateMETHODS: Monocentric study including 30 AHSCT-treated people with multiple sclerosis who performed at least two brain magnetic resonance imaging scans with susceptibility-weighted imaging either (i) before and after AHSCT (pre/post-AHSCT group; n = 12) or (ii) after AHSCT only (post-AHSCT group; n = 18).
interventionOBJECTIVE: To investigate longitudinal changes in PRL count in people with multiple sclerosis treated with autologous haematopoietic stem cell transplantation (AHSCT), exploring their potential as predictors of treatment response.
primary endpointRESULTS: In the pre/post-AHSCT group, PRL count decreased in 2/5 (40%) PRL-positive cases over a median of 21 (7-74) months; 5/26 (19%) PRL s resolved.
follow upRESULTS: In the pre/post-AHSCT group, PRL count decreased in 2/5 (40%) PRL-positive cases over a median of 21 (7-74) months; 5/26 (19%) PRL s resolved.
findingsRESULTS: In the pre/post-AHSCT group, PRL count decreased in 2/5 (40%) PRL-positive cases over a median of 21 (7-74) months; 5/26 (19%) PRL s resolved.
limitationsTitle: Autologous haematopoietic stem cell transplantation affects paramagnetic rim lesions in multiple sclerosis.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.